

1 Plasma proteomics reveals markers of metabolic stress in HIV infected children
2 with severe acute malnutrition: call for more evidence-based nutritional
3 intervention strategies
4

5 Gerard Bryan Gonzales^{1,2*}, James M Njunge^{3,4}, Bonface M Gichuki^{3,4}, Bijun Wen^{5,6}, Isabel
6 Potani³, Wieger Voskuil^{3,7,8}, Robert Bandsma^{3,5,6}, James A Berkley^{3,9}

- 7 1. Department of Gastroenterology, Faculty of Medicine and Health Sciences, Ghent
8 University, Ghent, Belgium
9 2. VIB Inflammation Research Centre, Ghent, Belgium
10 3. The Childhood Acute Illness & Nutrition (CHAIN) Network, Nairobi, Kenya
11 4. KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya
12 5. Centre for Global Child Health, The Hospital for Sick Children, Toronto, Ontario,
13 Canada
14 6. Department of Nutritional Sciences, Faculty of Medicine, University of Toronto,
15 Toronto, Canada
16 7. Global Child Health Group, Emma Children's Hospital, Amsterdam University
17 Medical Centres, Amsterdam, the Netherlands
18 8. Amsterdam Institute for Global Health and Development, Department of Global
19 Health, Amsterdam University Medical Centres, Amsterdam, The Netherlands
20 9. Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine,
21 University of Oxford, Oxford, UK
22

23 *Correspondence to:

24 Gerard Bryan Gonzales, PhD

25 Email: Gerard.gonzales@ugent.be

26 **Abstract (word count = 250)**

27

28 HIV infection affects up to 30% of children presenting with severe acute malnutrition (SAM)
29 in Africa and is associated with increased mortality. Children with SAM are treated similarly
30 regardless of the presence of HIV although mechanisms of nutritional recovery in HIV and/or
31 SAM are not well understood. We aimed to test the hypothesis that metabolic and
32 inflammatory perturbations among children with SAM differed between those with HIV (n =
33 54) and without HIV (n = 113) to better understand their specific nutritional and therapeutic
34 requirements. We performed a secondary analysis of a clinical trial and plasma proteomics
35 data among children with complicated SAM in Kenya and Malawi. Compared to children
36 with SAM without HIV, HIV-infected children had evidence (false discovery rate corrected
37 $p < 0.05$) of metabolic stress, including enriched pathways related to inflammation and lipid
38 metabolism. Moreover, we observed reduced plasma levels of zinc- α -2-glycoprotein,
39 butyrylcholinesterase, and increased levels of complement C2 resembling findings in
40 metabolic syndrome, diabetes and other non-communicable diseases. HIV was also associated
41 (false discovery rate corrected $p < 0.05$) with higher levels of plasma chemokines: MCP1,
42 CCL4, GCSF, IL1b, TNFa, IL-2, 5, 7, 8 and 15, IL12p40, IP-10, and IL-1RA. Considering
43 evidence of biomarkers of metabolic stress in children with HIV and SAM, it is of potential
44 concern that our current treatment strategy for SAM regardless of HIV status involves a high-
45 fat therapeutic diet. The results of this study indicate a need for clinical trials of therapeutic
46 foods that meet the specific metabolic needs of children with HIV and SAM.

47

48 **Keywords:** HIV, SAM, lipid metabolism, molecular nutrition

49 **Introduction**

50 Malnutrition, specifically undernutrition in all its forms, remains a global public health burden
51 that accounts for 45% of all death among children under 5 years old [1]. Despite careful
52 monitoring and adherence to guidelines set by the World Health Organization, although in
53 general, uncomplicated SAM cases treated in the community do well, up to 25% of children
54 with complicated severe acute malnutrition (SAM) treated in a hospital environment do not
55 survive [2-5]. Furthermore, about one in five children treated for complicated SAM and
56 discharged alive, die in the first year after discharge in low-resource settings [6-8]. However,
57 our understanding of the pathophysiology underlying the poor prognosis for these children is
58 surprisingly limited.

59

60 Infection with the human immunodeficiency virus (HIV) is a common co-morbidity of SAM
61 in sub-Saharan Africa affecting up to 30% of admissions among SAM cases [9]. HIV-infected
62 or exposed children are significantly more likely to be stunted, wasted, and underweight [10].
63 They also more often present with other clinical complications and greater susceptibility to
64 infections, thus further complicating their clinical management, which may include providing
65 more aggressive antimicrobial therapy and higher caloric nutritional intervention [11].
66 Moreover, response to clinical management is also less predictable and less well-understood
67 in HIV-infected children compared to their uninfected counterparts [12]. Although acute
68 opportunistic infections play a key role in the outcome of these children, intestinal pathology
69 including inflammation and malabsorption, and metabolic perturbations may also be present.
70 However, mechanisms driving poor nutritional recovery of children with HIV even when
71 detected co-morbidities are treated remain poorly understood [12].

72

73 We hypothesised that inflammatory, metabolic and other pathways which are likely to be
74 involved in the response to infection, survival and nutritional recovery differ between children
75 with SAM with and without HIV. We conducted a secondary analysis of data and biological
76 samples from a randomised clinical trial in Kenya and Malawi [13].

77

78 **Materials and Methods**

79 **Patient recruitment and study design**

80 This is a secondary analysis of a nested case control study from a randomised controlled trial
81 (NCT02246296), which tested the effect of a lactose-free, low-carbohydrate F75 milk to limit
82 carbohydrate malabsorption, diarrhoea and refeeding syndrome among children hospitalized
83 for complicated SAM at Queen Elizabeth Central Hospital in Blantyre, Malawi, Kilifi County
84 Hospital and Coast General Hospital, Mombasa, Kenya [13]. Children aged 6 months to 13
85 years were eligible for enrolment into the trial at admission to hospital if they had SAM,
86 defined as: mid-upper arm circumference (MUAC) <11.5cm or weight-for-height Z score <-3
87 if younger than 5 years of age, BMI Z score <-3 if older than 5 years, or oedematous
88 malnutrition at any age and had medical complications or failing an appetite test, as defined
89 by WHO guidelines [14]. Children were excluded if they had a known allergy to milk
90 products and did not provide consent. Biological samples were obtained before the children
91 received the randomised treatment irrespective of HIV status. Unless an HIV positive status
92 was documented, HIV status was assessed by offering an antibody test at admission. For this
93 analysis, patients that tested positive on an HIV antibody test were considered HIV(+) and
94 children with missing or declined HIV test were excluded.

95

96 The nested case-control study was designed to investigate inpatient mortality for which
97 proteomic, cytokine, and chemokine data was generated using plasma samples collected at

98 admission during enrolment to the trial. To compare the proteomic profiles between HIV
99 affected and non-affected children with SAM, we used data from a nested case-control study
100 to investigate inpatient mortality during the trial including 79 deaths and 88 children that were
101 clinically stabilized and discharged from the hospital matched by site of recruitment. For this
102 analysis, all observations from the proteomics dataset were included and the analysis was
103 designed to help overcome selection bias, as given in detail below.

104

105 **Proteomics, cytokine and chemokine analysis**

106 Untargeted proteomics and targeted cytokines and chemokines analysis of plasma samples
107 were performed following methods described previously [15]. The targeted protein panel
108 included: epidermal growth factor (EGF); eotaxin; granulocyte-colony stimulating factor
109 (GCSF); granulocyte-macrophage colony-stimulating factor (GMCSF); interferon alpha-2
110 (IFNa2); interferon gamma (IFNg); interleukins 10, 12p40, 12p70, 13, 15, 17A, 1a, 1b, 1RA,
111 2 to 8; interferon gamma-induced protein 10 (IP10); monocyte chemoattractant protein 1
112 (MCP1), macrophage inflammatory protein 1 alpha and beta (MIP1a & b); tumour necrosis
113 factor alpha (TNFa) and beta (TNFb); and vascular endothelial growth factor (VEGF).

114

115 **Data analysis**

116 Data analyses were performed using R v3.5 [16]. Analysis of the prevalence of HIV(+),
117 nutritional status and their associations with inpatient mortality utilised the entire trial dataset
118 (N=843). Analysis of categorical data was performed using Fisher's test and generalised
119 linear models for continuous outcomes. Logistic regression was used to analyse binary
120 outcomes adjusting for age, sex, presence of oedema, and site of recruitment. These
121 associations were also adjusted for MUAC. As a sensitivity analysis to address the possibility
122 of confounding due to HIV maternal antibodies in younger children, a test of interaction

123 between age above or below 18 months and individual proteins towards HIV status was
124 performed.

125

126 The proteomics, cytokines and chemokines analyses were secondary analyses of data
127 collected from a nested case-control study with inpatient mortality as its primary outcome,
128 hence with strong selection bias. The analysis for the association between HIV status and
129 individual proteins was therefore performed using logistic regression analysis with inverse
130 probability weighting (IPW) to correct for selection bias [17-20]. Weights (w) were calculated
131 as suggested by Samuelsen [18] wherein the weight for each observation selected into the
132 nested case-control study was computed as the inverse of the probability of being selected for
133 the nested study from the main clinical trial. The probability of inclusion was therefore
134 calculated as:

135

$$136 \quad p(i) = \frac{1}{1 + e^{-(\beta_0 + \beta_1 x_1 + \beta_2 x_2 \dots + \beta_n x_n)}};$$

137 where $p(i)$ is the probability of inclusion in the nested case-control study and $x_1, x_2 \dots x_n$ are
138 HIV status, sex, age, presence of oedema, mid-upper arm circumference, and site of
139 recruitment of the i -th observation (child) based on the entire trial population. Inverse
140 probability weight is therefore:

141

$$142 \quad w(i) = \frac{1}{p(i)}$$

143

144 Differences in individual proteins abundances were considered statistically significant when
145 $p < 0.05$ after adjustment for multiple comparisons using Benjamini-Hochberg false discovery
146 rate (FDR) [21].

147

148 Multivariate analysis was undertaken in order to determine several proteins that are
149 collectively associated with HIV status, some of which may not be significantly associated to
150 HIV independently. This was performed using a weighted elastic net (EN) model
151 implemented using the “glmnet” package in R [22]. EN is a penalized regression approach
152 that was developed to help overcome problems caused by high dimensional data. It is an
153 integration of two regularized approaches, ridge regression and least absolute shrinkage and
154 selection operator (LASSO), wherein the contribution of each of these models to the final EN
155 model is controlled by the α parameter [22, 23]. The strong penalization imposed by LASSO
156 draws coefficients to zero thereby eliminating non-predictive proteins features, whereas ridge
157 regression addresses potential multi-collinearity problems in high-dimensional data [22, 23].

158

159 Weighted EN model generation was performed with HIV status as outcome, protein profile as
160 predictors, and w as observation weights. The penalization parameter lambda, which
161 influences the shrinkage of variable coefficients to zero thus eliminating some non-
162 contributing variables, was determined by estimating the area under the receiver operator
163 curve (ROC) of the population using ten-fold cross validation. Several alpha parameter values
164 were assessed and a final value of 0.85 was taken to achieve a compromise between
165 predictive ability and fewer number of features extracted. The final lambda parameter was
166 based on the value which gave the highest area under the ROC (AUROC) value.

167

168 Proteins with significant association with HIV status after correction for false discovery and
169 those extracted by the EN model were then uploaded to The Database for Annotation,
170 Visualization and Integrated Discovery (DAVID) v6.8 Bioinformatics Resource [24] to assess
171 the Gene ontology (GO) enriched pathways of the differentially expressed proteins.

172

173 EN model validity was judged based on the AUROC and misclassification error rate. The
174 fitted EN model performance measured as optimism-corrected AUC was validated using
175 bootstrap, following the procedure of Smith et al. [25]. Bootstrapping was performed on 2000
176 iterations using the “BootValidation” package in R. Protein features extracted at least 80% of
177 all iterations by the bootstrap EN model were then considered to be the most relevant protein
178 biomarkers. These proteins were then fitted on a weighted logistic regression with HIV as
179 outcome.

180

181 **Visualisation of significantly enriched GO terms**

182 Bubble plots were used to visualise the significantly enriched pathways ($p < 0.05$ after
183 adjustment for FDR) obtained from DAVID. The p-values in DAVID were obtained using a
184 modified Fisher’s exact test [26]. The y-axis represents the fold enrichment which indicates
185 the magnitude of the enrichment, as calculated in DAVID. Fold enrichment is defined as:

$$186 \quad \text{fold enrichment} = \frac{(m/n)}{M/N},$$

187 where m is the number of proteins significantly associated with HIV status or proteins
188 extracted by the EN model that belong to a particular pathway, while M is the total number of
189 proteins belonging to the same pathway. Variable n is the number of all proteins significantly
190 associated with HIV status or extracted by the EN model and N is the total number of all
191 proteins in the human background. Therefore, a fold enrichment of 10 indicates that 10% of
192 the proteins significantly associated with HIV status belong to a particular pathway, and 1%
193 of all annotated proteins in the human background belongs to the same pathway [26].
194 However, the proponents of this metric warns that big fold enrichments could be obtained
195 from a small number of proteins, which could be due to small n or pathways with fewer
196 members.

197

198 The x-axis on the hand represents the enrichment z-score for a particular pathway [27], which
199 is calculated as follows:

$$200 \quad z - score = \frac{(up-down)}{\sqrt{count}};$$

201 where *up* is the total number of proteins upregulated, *down* is the total number of proteins
202 downregulated, and *count* is the total number of proteins in the input which belongs to a
203 particular pathway. Variables *up* and *down* were based on the weighted logistic regression for
204 each individual protein. Hence, if 5 proteins belonging to pathway *x* were upregulated and 2
205 were downregulated, the z-score for pathway *x* would be: $(5-2)/\sqrt{7} = 1.13$. A positive z-score
206 indicates that the particular pathway is overall upregulated in HIV(+), whereas a negative z-
207 score indicates an overall downregulation [27].

208

209 **Results**

210 **Patient characteristics**

211 Table 1 presents the baseline characteristics of the children in the randomised trial. A total of
212 843 complicated SAM children were recruited for the randomised trial, of which 179 (22%)
213 patients were HIV(+). Age was higher and MUAC was lower in HIV(+) children than HIV(-)
214 counterparts. Most HIV cases were found in Malawi. Sex and the presence of oedema were
215 not associated with HIV status. Mortality was more than 2 times higher among in HIV(+)
216 compared to HIV(-) ($p < 0.001$). Children whose HIV status were unknown had the highest
217 mortality of 34%, which indicates the need for more active HIV screening among children
218 with SAM.

219

220 Among HIV(+), 33% were already under an anti-retroviral treatment (ART) regime: 53/179
221 (30%) on highly active antiretroviral therapy (HAART), and 7/179 (4%) on Nevirapine only.

222 About half of the children (90/179) were naïve for ART whereas HIV treatment status was

223 unknown for 16% (29/179). Mortality was not significantly different among children on
224 HAART, ART naïve and children with unknown HIV treatment status (Supplementary Table
225 1).

226

227 **HIV is associated with increased inflammatory and immune response, dysregulated lipid**
228 **metabolism, and increased proteolysis in children with SAM**

229 Table 2 shows the characteristics for children included in the proteomics study. Fifty four
230 HIV (+) children were compared to 113 HIV(-) children with SAM. In this sub-population,
231 age was not significantly associated with HIV, and as in the full dataset. HIV(+) children also
232 had significantly lower MUAC and higher mortality than HIV(-) children. There were no
233 significant associations between sex and presence of oedema with HIV status.

234

235 A total of 204 circulating proteins were annotated and compared between children with and
236 without HIV infection. Of these, levels of 42 proteins were found to be significantly
237 associated with HIV status in the initial univariate analysis (Figure 1A) (Supplementary table
238 2). Specifically, HIV(+) was associated with higher circulating levels of immunoglobulins,
239 inflammatory proteins such as calprotectin (S100 calcium binding protein A8 and S100
240 calcium binding protein A9), complement proteins, and proteins related to host response to
241 infection (i.e. lipopolysaccharide binding protein, galectin 3 binding protein and CD5
242 molecule-like protein). Enrichment analysis suggested that HIV(+) children have increased
243 complement activation and immune response, and inflammatory responses than HIV(-)
244 children. Neutrophil aggregation and chemokine production appeared to be the pathways most
245 highly enriched in HIV(+) compared to HIV(-) SAM children. To substantiate these results,
246 we quantified chemokine and cytokine levels in plasma. As shown, most chemokines had the
247 tendency to be associated with HIV infection, where elevated plasma concentration of 12

248 were significantly associated with HIV status in SAM children (Figure 1B), namely:
249 monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1 beta
250 (MIP1b, CCL4), granulocyte colony-stimulating factor (GCSF), interleukin 1 beta (IL1b),
251 tumour necrosis factor alpha (TNF α), interleukins 2,5,7, 8 and 15 (IL2 , 5, 7, 8, 15),
252 interleukin 12 subunit beta (IL12p40), interferon gamma-induced protein 10 (IP-10), and
253 interleukin-1 receptor antagonist (IL-1RA).

254

255 Out of the 43 differentially expressed proteins, three proteins were found to be negatively
256 associated with HIV status on initial univariate analysis, namely: adiponectin, kininogen-1
257 and peptidase inhibitor 16. Among HIV(+) children, there were no statistically significant
258 associations with receiving HAART (n = 53) compared to ART naïve (n = 90) children (data
259 not shown), although our study may not be powered to observe significant difference for this
260 comparison. Furthermore, sensitivity analysis to address the possibility of HIV maternal
261 antibodies in younger children, showed no significant interaction of age above or below 18
262 months and individual proteins plasma levels towards HIV status.

263

264 The weighted EN model extracted 73 circulating proteins (Figure 2A) that are associated with
265 HIV status with AUROC = 0.97 [95% CI: 0.95 – 0.99] (Figure 2B) and misclassification error
266 rate of 2.4%. Optimism-adjusted validated AUROC after bootstrapping was 0.90 [95% CI:
267 0.90 – 0.90], indicating a robust model. Pathway enrichment analysis highlighted that apart
268 from increased immune response, HIV(+) children with SAM have increased proteolysis and
269 lipid mobilisation, specifically increased very low-density lipoprotein assembly, indicating
270 metabolic dysregulation related to cholesterol and triglyceride metabolism among HIV(+)
271 patients (Figure 2D).

272

273 After 2000 bootstrap iterations during bootstrap validation, 3 proteins were consistently
274 extracted by the EN model >80% of the time (Figure 2E), namely: butyrylcholinesterase
275 (BChE), complement C2 and zinc- α -2-glycoprotein (ZAG), indicating that these 3 proteins
276 are likely to be the most important features associated with HIV in children with complicated
277 SAM. Weighted logistic regression model of these 3 proteins showed good discrimination of
278 HIV status (AUROC = 0.80 [95% CI: 0.74 – 0.87]) (Figure 2F).

279

280 **Discussion**

281 In this study, we report plasma proteomic differences associated with HIV status, which
282 indicates that HIV imposes additional metabolic and inflammatory insults among HIV(+)
283 children with SAM. Our results show that pathways involved in inflammatory response,
284 complement cascade activation and lipid metabolism dysregulation are associated with HIV
285 status. Levels of several plasma chemokines were also found to be higher in HIV(+) among
286 children with SAM. Greater inflammatory responses in these children could be related to the
287 higher inpatient mortality of HIV(+) compared to HIV(-) children with SAM.

288

289 An earlier metabolomics study in Uganda reported reduced serum levels of adiponectin and
290 leptin, whereas serum triglycerides, ketones and even-chain acylcarnitines were higher in
291 HIV(+) children with SAM indicating perturbed lipid metabolism [28]. Our current study
292 therefore concurs with this finding, as we also found reduced plasma levels of adiponectin in
293 HIV(+) SAM children compared to HIV(-) SAM children, along with upregulation of
294 pathways involved in lipid transport and metabolism, specifically very low-density lipoprotein
295 assembly.

296

297 Using optimism-adjusted bootstrap validation of the EN model, we found 3 proteins:
298 complement c2, BChE and ZAG robustly distinguished HIV(+) from HIV(-) in children with
299 SAM, demonstrating the ability of multivariate analysis techniques, such as EN, to uncover
300 underlying relationships between protein markers which would be difficult to identify when
301 analysed individually. The activation of the complement system during HIV infection has
302 been previously discussed at length, which is associated with the increased cellular invasion
303 of HIV in cells [29-31]. On the other hand, in a recent study in China, low circulating BChE
304 was found to be highly associated with HIV severity, was predictive of mortality in adults,
305 and was proposed as a plausible strategy for severity classification among adults with HIV
306 [32]. BChE is also reported to be reduced in protein-energy malnutrition, stress and
307 inflammation [33]. In animal studies, BChE deficiency was found to strongly affect fat
308 metabolism and promotes hepatic lipid accumulation [34]. Serum BChE levels have been
309 found to have a significant negative correlation with serum total cholesterol and serum low-
310 density-lipoprotein cholesterol among people with diabetes mellitus [35]. Furthermore,
311 reduced plasma levels of ZAG, an adipokine with protective effect against insulin resistance,
312 was previously reported to be implicated in dyslipidaemia in HIV(+) adults under ART
313 treatment [36]. Reduced circulating levels of ZAG has also been found among adults with
314 clinically diagnosed metabolic syndrome, based on guidelines of the United States National
315 Cholesterol Education Program (NCEP) Expert Panel Adult Treatment Panel (ATP) III
316 criteria [37]. Serum ZAG levels have been reported lower among adults with impaired
317 glucose tolerance and type 2 diabetes mellitus [38]. Taken together, our results therefore
318 suggest that children with both HIV and SAM children manifest hallmarks of metabolic stress
319 similar to those occurring in metabolic syndrome and other non-communicable diseases
320 (NCD).

321

322 The results of this study is the first proteomics investigation on the interaction between HIV
323 and SAM, which together with the previously published metabolomics study [28], provides
324 more evidence on the increased metabolic stress and altered metabolic response among
325 children living with both HIV and SAM. Our results also concur with previous studies that
326 reported elevated metabolic stress among non-malnourished adults living with HIV leading to
327 increased prevalence or risk for metabolic syndrome, cardiovascular diseases, diabetes and
328 other non-communicable diseases [39-45].

329

330 However, despite our knowledge that HIV-infected populations have altered metabolic
331 requirements compared to HIV-uninfected counterparts, WHO guidelines for the nutritional
332 management for SAM are globally the same regardless of HIV status, which is summarized in
333 Table 3 [46]. Nutritional management for in-patient children with SAM involves provision of
334 a low-protein, low-fat milk-based food, F75, every few hours. F75 is used during clinical
335 stabilization occurring during the first few days after admission and is not intended for weight
336 gain. Once the children are clinically stabilized and are able to tolerate the solute load,
337 children are transitioned to F100, a higher-calorie, high-fat milk intended to boost weight
338 gain. Upon discharge from in-patient care, children are referred to community based
339 nutritional therapeutic centres where they are provided with ready-to-use therapeutic food
340 (RUTF), a peanut-based calorie-dense diet.

341

342 Considering evidence of biomarkers of metabolic syndrome and NCD in HIV(+) children
343 with SAM, it is of potential concern that our current treatment strategy involves a high-fat
344 therapeutic diet. About 50% of much needed calories during the growth catch-up phase are
345 supplied as lipids, which HIV(+) children may not be able to efficiently assimilate.
346 Alterations in lipid metabolism in HIV(+) children with SAM may also mean that the high

347 amounts of dietary lipids could be deposited as ectopic fat in the liver and muscle,
348 predisposing to insulin resistance, diabetes, cardiovascular problems and other NCDs later in
349 life. Although long-term metabolic follow-up studies could be done for HIV(+) children
350 previously treated for either complicated and uncomplicated SAM, significant barriers are the
351 high mortality rate in earlier studies of HIV(+) children with SAM, cost and difficulty tracing
352 them years later. The results of this study indicate a need for clinical trials modifying the
353 composition of F100 or RUTF to meet the specific metabolic needs of HIV(+) children with
354 SAM. This could initially be done in relatively small groups with outcomes that include
355 measuring metabolic stress.

356

357 Several studies on nutritional intervention strategies among HIV-infected adults have been
358 reported. For instance, a study in the USA showed that dietary fat intake, specifically
359 saturated fats, was significantly associated with hypertriglyceridemia among HIV-infected
360 adults (18 – 60 years) [47]. Moreover, in a preclinical model, high saturated fat consumption
361 was found to accelerate immunodeficiency virus disease progression in macaques, specifically
362 increased mortality hazard and circulating levels of pro-inflammatory cytokines, especially
363 IL8 [48], which has been previously reported to be associated with lipodystrophy among HIV
364 patients [49]. In our study, we also found a significant association between high plasma IL8
365 concentration and HIV in SAM children. Hence, modifying the saturated fat composition of
366 the milk-based F75 and F100 could potentially lower metabolic stress.

367

368 Furthermore, the European Society for Parenteral and Enteral Nutrition (ESPEN) gave a grade
369 A recommendation for the use of medium-chain triglyceride (MCT)-based diet on HIV(+)
370 patients with diarrhoea and severe undernutrition in its 2006 ESPEN Guidelines on Enteral
371 Nutrition [50]. Grade A recommendations are given to strategies based on meta-analysis or at

372 least one randomised control trial. In this case, the recommendation was based on a
373 prospective, randomized double-blind comparative trial on 24 adult patients with HIV and
374 diarrhoea of more than 4-wk duration, fat malabsorption, and loss of 10–20% of ideal body
375 weight [51]. In this study, the authors found improved outcomes from diarrhoea and fat
376 malabsorption from MCT than long-chain triglyceride-based diet among HIV(+) adults.

377

378 Lastly, the long-term metabolic effect of nutritional intervention strategies for SAM still
379 remains unresolved. Most specifically, the potential metabolic stress associated with the rapid
380 weight gain during the nutritional rehabilitation phase after SAM and its implications on
381 nutritional outcomes during adulthood demands urgent research attention, especially for
382 HIV(+) children with SAM.

383

384 **Conclusion**

385 Plasma proteomics reveals that HIV(+) children with SAM manifest hallmarks of metabolic
386 stress similar to those observed in non-communicable diseases. This could be related to the
387 poor nutritional recovery and high mortality of HIV(+) children with SAM despite clinical
388 and nutritional intervention. The results of this study indicate a need for clinical trials
389 modifying the composition of F100 or RUTF to meet the specific metabolic needs of HIV(+)
390 children with SAM during rehabilitation phase. This could initially be done in relatively small
391 groups with outcomes that include measuring metabolic stress.

392

393 **Acknowledgements**

394 The original clinical trial was supported by the Thrasher Fund (grant number: 9403), awarded
395 to JAB. GBG is a postdoctoral fellow of the Research Foundation – Flanders (FWO). The
396 Ghent University –VLIR-UOS Global Minds Fund supported the travel of GBG to Kenya.

397 JAB and JMN are currently supported by the Bill & Melinda Gates Foundation within the
398 Childhood Acute Illness and Nutrition (CHAIN) Network (grant OPP1131320). JAB is
399 currently supported by the MRC/DfID/Wellcome Trust Joint Global Health Trials scheme
400 (grant MR/M007367/1). The funders had no role in the design, conduct, analysis, or writing
401 of this manuscript.

402

403 **Study approvals**

404 The secondary analyses of the trial were approved by the Kenyan national ethics committee,
405 KEMRI- SERU (KEMRI/RES/7/3/1). The trial was registered at clinicaltrials.gov
406 (NCT02246296).

407

408 **Author contributions**

409 GBG, JMN and JAB designed the study and data analysis. JMN and BG performed the
410 proteomics analysis. GBG performed data analysis. BW, RB, WV, IP and JAB were involved
411 in the clinical aspects of the study. GBG wrote the initial drafts of the manuscript and all
412 authors contributed to editing and improving the manuscript.

413

414 **References**


- 415 1. Black, R.E., et al., *Maternal and child undernutrition and overweight in low-income*
416 *and middle-income countries*. The Lancet, 2013. **382**(9890): p. 427-451.
- 417 2. Heikens, G.T., et al., *Case management of HIV-infected severely malnourished*
418 *children: challenges in the area of highest prevalence*. Lancet, 2008. **371**(9620): p.
419 1305-7.
- 420 3. Irena, A.H., M. Mwambazi, and V. Mulenga, *Diarrhea is a Major killer of Children*
421 *with Severe Acute Malnutrition Admitted to Inpatient Set-up in Lusaka, Zambia*.
422 *Nutrition Journal*, 2011. **10**: p. 110-110.
- 423 4. Maitland, K., et al., *Children with Severe Malnutrition: Can Those at Highest Risk of*
424 *Death Be Identified with the WHO Protocol?* PLOS Medicine, 2006. **3**(12): p. e500.
- 425 5. Hossain, M., et al., *Efficacy of World Health Organization guideline in facility-based*
426 *reduction of mortality in severely malnourished children from low and middle income*
427 *countries: A systematic review and meta-analysis*. J Paediatr Child Health, 2017.
428 **53**(5): p. 474-479.

- 429 6. Kerac, M., et al., *Follow-Up of Post-Discharge Growth and Mortality after Treatment*
430 *for Severe Acute Malnutrition (FuSAM Study): A Prospective Cohort Study*. PLOS
431 ONE, 2014. **9**(6): p. e96030.
- 432 7. Berkley, J.A., et al., *Daily co-trimoxazole prophylaxis to prevent mortality in children*
433 *with complicated severe acute malnutrition: a multicentre, double-blind, randomised*
434 *placebo-controlled trial*. Lancet Glob Health, 2016. **4**(7): p. e464-73.
- 435 8. Nemetchek, B., et al., *Paediatric postdischarge mortality in developing countries: a*
436 *systematic review*. BMJ Open, 2018. **8**(12): p. e023445.
- 437 9. Fergusson, P. and A. Tomkins, *HIV prevalence and mortality among children*
438 *undergoing treatment for severe acute malnutrition in sub-Saharan Africa: a*
439 *systematic review and meta-analysis*. Trans R Soc Trop Med Hyg, 2009. **103**(6): p.
440 541-8.
- 441 10. Ndirangu, M., et al., *Nutritional status of under-five children in HIV-affected*
442 *households in western Kenya*. Food Nutr Bull, 2011. **32**(2): p. 159-67.
- 443 11. Rose, A.M., C.S. Hall, and N. Martinez-Alier, *Aetiology and management of*
444 *malnutrition in HIV-positive children*. Archives of Disease in Childhood, 2014. **99**(6):
445 p. 546-551.
- 446 12. Trehan, I., et al., *Challenges in the Management of HIV-Infected Malnourished*
447 *Children in Sub-Saharan Africa*. AIDS Research and Treatment, 2012. **2012**: p. 8.
- 448 13. Bandsma, R.H.J., et al., *A reduced-carbohydrate and lactose-free formulation for*
449 *stabilization among hospitalized children with severe acute malnutrition: A double-*
450 *blind, randomized controlled trial*. PLoS Med, 2019. **16**(2): p. e1002747.
- 451 14. WHO. *Management of severe malnutrition: a manual for physicians and other senior*
452 *health workers*. 1999 May 2019]; Available from:
453 <http://apps.who.int/iris/bitstream/10665/41999/1/a57361.pdf>.
- 454 15. Njunge, J.M., et al., *Biomarkers of post-discharge mortality among children with*
455 *complicated severe acute malnutrition*. Scientific Reports, 2019. **9**(1): p. 5981.
- 456 16. R Core Team. *R: A language and environment for statistical computing*. R Foundation
457 *for Statistical Computing*. 2017; Available from: <https://www.R-project.org/>.
- 458 17. Kim, R.S. and R.C. Kaplan, *Analysis of secondary outcomes in nested case-control*
459 *study designs*. Statistics in medicine, 2014. **33**(24): p. 4215-4226.
- 460 18. Samuelsen, S.O., *A Pseudolikelihood Approach to Analysis of Nested Case-Control*
461 *Studies*. Biometrika, 1997. **84**(2): p. 379-394.
- 462 19. Pan, Y., et al., *Secondary outcome analysis for data from an outcome-dependent*
463 *sampling design*. Statistics in Medicine, 2018. **37**(15): p. 2321-2337.
- 464 20. Jiang, Y., A.J. Scott, and C.J. Wild, *Secondary analysis of case-control data*. Statistics
465 *in Medicine*, 2006. **25**(8): p. 1323-1339.
- 466 21. Benjamini, Y. and Y. Hochberg, *Controlling the False Discovery Rate: A Practical*
467 *and Powerful Approach to Multiple Testing*. Journal of the Royal Statistical Society.
468 Series B (Methodological), 1995. **57**(1): p. 289-300.
- 469 22. Friedman, J.H., T. Hastie, and R. Tibshirani, *Regularization Paths for Generalized*
470 *Linear Models via Coordinate Descent*. 2010, 2010. **33**(1): p. 22.
- 471 23. Zou, H. and T. Hastie, *Regularization and variable selection via the elastic net*.
472 *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*, 2005.
473 **67**(2): p. 301-320.
- 474 24. Huang, D.W., B.T. Sherman, and R.A. Lempicki, *Systematic and integrative analysis*
475 *of large gene lists using DAVID bioinformatics resources*. Nat. Protocols, 2008. **4**(1):
476 p. 44-57.
- 477 25. Smith, G.C.S., et al., *Correcting for Optimistic Prediction in Small Data Sets*.
478 *American Journal of Epidemiology*, 2014. **180**(3): p. 318-324.

- 479 26. Huang da, W., B.T. Sherman, and R.A. Lempicki, *Systematic and integrative analysis*
480 *of large gene lists using DAVID bioinformatics resources*. Nat Protoc, 2009. **4**(1): p.
481 44-57.
- 482 27. Walter, W., F. Sanchez-Cabo, and M. Ricote, *GOplot: an R package for visually*
483 *combining expression data with functional analysis*. Bioinformatics, 2015. **31**(17): p.
484 2912-4.
- 485 28. Mody, A., et al., *Effects of HIV infection on the metabolic and hormonal status of*
486 *children with severe acute malnutrition*. PLoS One, 2014. **9**(7): p. e102233.
- 487 29. Tacnet-Delorme, P., et al., *In Vitro Analysis of Complement-Dependent HIV-1 Cell*
488 *Infection Using a Model System*. The Journal of Immunology, 1999. **162**(7): p. 4088.
- 489 30. Stoiber, H., et al., *The supportive role of complement in HIV pathogenesis*.
490 Immunological Reviews, 2001. **180**(1): p. 168-176.
- 491 31. Stoiber, H., C. Speth, and M.P. Dierich, *Role of complement in the control of HIV*
492 *dynamics and pathogenesis*. Vaccine, 2003. **21**: p. S77-S82.
- 493 32. Xu, L., et al., *Butyrylcholinesterase Levels on Admission Predict Severity and 12-*
494 *Month Mortality in Hospitalized AIDS Patients*. Mediators Inflamm, 2018. **2018**: p.
495 5201652.
- 496 33. Santarpia, L., et al., *Butyrylcholinesterase as a prognostic marker: a review of the*
497 *literature*. J Cachexia Sarcopenia Muscle, 2013. **4**(1): p. 31-9.
- 498 34. Chen, V.P., et al., *Butyrylcholinesterase Deficiency Promotes Adipose Tissue Growth*
499 *and Hepatic Lipid Accumulation in Male Mice on High-Fat Diet*. Endocrinology,
500 2016. **157**(8): p. 3086-95.
- 501 35. Sridhar, G., et al., *Serum butyrylcholinesterase in type 2 diabetes mellitus: a*
502 *biochemical and bioinformatics approach*. Lipids in Health and Disease, 2005. **4**(1): p.
503 18.
- 504 36. Ceperuelo-Mallafre, V., et al., *Zinc alpha-2 glycoprotein is implicated in*
505 *dyslipidaemia in HIV-1-infected patients treated with antiretroviral drugs*. HIV Med,
506 2012. **13**(5): p. 297-303.
- 507 37. Lei, L., et al., *Circulating zinc- α 2-glycoprotein levels are low in newly diagnosed*
508 *patients with metabolic syndrome and correlate with adiponectin*. Nutrition &
509 Metabolism, 2017. **14**(1): p. 53.
- 510 38. Yang, M., et al., *Zinc- α 2-glycoprotein is associated with insulin resistance in humans*
511 *and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration:*
512 *cross-sectional and interventional studies in normal subjects, insulin-resistant*
513 *subjects, and subjects with newly diagnosed diabetes*. Diabetes care, 2013. **36**(5): p.
514 1074-1082.
- 515 39. Bastard, J.P., et al., *Diabetes and dyslipidaemia are associated with oxidative stress*
516 *independently of inflammation in long-term antiretroviral-treated HIV-infected*
517 *patients*. Diabetes Metab, 2019.
- 518 40. Nix, L.M. and P.C. Tien, *Metabolic syndrome, diabetes, and cardiovascular risk in*
519 *HIV*. Curr HIV/AIDS Rep, 2014. **11**(3): p. 271-8.
- 520 41. Sobieszczyk, M.E., et al., *Metabolic Syndrome After HIV Acquisition in South African*
521 *Women*. J Acquir Immune Defic Syndr, 2016. **73**(4): p. 438-445.
- 522 42. Policarpo, S., et al., *Cardiovascular risk in HIV-infected individuals: A comparison of*
523 *three risk prediction algorithms*. Rev Port Cardiol, 2019. **38**(7): p. 463-470.
- 524 43. Lagathu, C., et al., *Metabolic complications affecting adipose tissue, lipid and glucose*
525 *metabolism associated with HIV antiretroviral treatment*. Expert Opin Drug Saf, 2019.
526 **18**(9): p. 829-840.


- 527 44. Sears, S., et al., *Metabolic Syndrome Among People Living with HIV Receiving*
528 *Medical Care in Southern United States: Prevalence and Risk Factors*. *AIDS Behav*,
529 2019.
- 530 45. Seth, A. and K.E. Sherman, *Fatty liver disease in persons with HIV infection*. *Top*
531 *Antivir Med*, 2019. **27**(2): p. 75-82.
- 532 46. Trehan, I. and M.J. Manary, *Management of severe acute malnutrition in low-income*
533 *and middle-income countries*. *Arch Dis Child*, 2015. **100**(3): p. 283-7.
- 534 47. Joy, T., et al., *Dietary fat intake and relationship to serum lipid levels in HIV-infected*
535 *patients with metabolic abnormalities in the HAART era*. *AIDS (London, England)*,
536 2007. **21**(12): p. 1591-1600.
- 537 48. Mansfield, K.G., et al., *A diet high in saturated fat and cholesterol accelerates simian*
538 *immunodeficiency virus disease progression*. *J Infect Dis*, 2007. **196**(8): p. 1202-10.
- 539 49. Lindegaard, B., et al., *Adipose tissue expression of IL-18 and HIV-associated*
540 *lipodystrophy*. *Aids*, 2004. **18**(14): p. 1956-8.
- 541 50. Ockenga, J., et al., *ESPEN Guidelines on Enteral Nutrition: Wasting in HIV and other*
542 *chronic infectious diseases*. *Clinical Nutrition*, 2006. **25**(2): p. 319-329.
- 543 51. Wanke, C.A., et al., *A medium chain triglyceride-based diet in patients with HIV and*
544 *chronic diarrhea reduces diarrhea and malabsorption: A prospective, controlled trial*.
545 *Nutrition*, 1996. **12**(11): p. 766-771.
546
547

548 Figures
549



550

551 Figure 1. (A) Volcano plot showing several significantly different (FDR adjusted p value <
552 0.05) proteins and their log₂ HIV(+) versus HIV(-) fold change. Red points represent those
553 significantly higher in plasma of HIV(-), blue points significantly enriched in plasma of
554 HIV(+) and orange points significantly higher than 1.5 folds in HIV(+) compared to HIV(-)
555 SAM children. Vertical lines indicate significance level at $p = 0.05$ and 0.01 ; horizontal lines
556 indicate more than 1.5 folds enrichment. (B) Log odds plots showing association of
557 chemokine markers analysed using Luminex platform and HIV status. Points indicate log
558 odds ratio for every log increase in plasma protein concentration; bars indicate 95%
559 confidence interval. (C) Gene ontology (GO-terms) enrichment analysis of proteins
560 significantly higher in plasma showing biologically relevant processes heightened among
561 HIV(+) SAM children. X-axis represents z-scores; y-axis, fold enrichment, and size of the
562 spheres represent the number of proteins involved in the particular pathway. Only
563 significantly enriched pathways ($p < 0.05$ after FDR adjustment) are plotted. See main text for
564 explanation of the plots. Pathways enriched are identified in the table
565



566

567 Figure 2. (A) Elastic net (EN) regularized regression lambda parameter optimization curve,
 568 optimal lambda parameter was chosen based on the highest area under the receiver operator
 569 curve (AUROC); (B) AUROC (0.97 [95% CI: 0.95 – 0.99]) of the EN model generated using
 570 the lambda parameter, alpha parameter was set to 0.75, final model extracted 34 protein
 571 features; (C) optimism-adjusted bootstrap validation of the generated EN model, validated
 572 AUROC = 0.90 [95% CI: 0.90 – 0.90] using 2000 iterations; (D) Gene ontology (GO-terms)
 573 enrichment analysis of proteins extracted by the EN model. X-axis represents z-scores; y-axis,
 574 fold enrichment, and size of the spheres represent the number of proteins involved in the
 575 particular pathway. Gold circles represent pathways enriched in HIV(+) whereas blue circles
 576 are pathways more associated with HIV(-). The grey circle indicate that there are as much
 577 proteins in this pathway that are significantly upregulated and downregulated in HIV. Only
 578 significantly enriched pathways ($p < 0.05$ after FDR adjustment) are plotted. See main text for
 579 explanation of the plots. Pathways enriched are identified in the table. (E) Log odds ratio plot

580 of the 3 proteins extracted after bootstrap validation with log odds on the x-axis and bars
581 indicating 95% confidence interval obtained using weighted logistic regression with HIV as
582 outcome variable and the 3 proteins as covariates. Weights used were obtained by inverse
583 probability of treatment weights; (F) Predictive ability of the weighted logistic regression
584 model using the 3 bootstrap validated proteins with HIV as outcome variable, AUROC = 0.80
585 [95% CI: 0.73 – 0.87]

586

587

588 Tables

589 Table 1. Descriptive characteristics of the study participants

	All	HIV (+)	HIV (-)	Unknown HIV status	<i>p</i> *
n (%)	843	179 (21%)	618 (73%)	46 (5%)	
Median age in months [IQR]	16 [10 – 25]	21 [12 – 31]	16 [10 – 25]	10 [8 – 17]	<0.001
% girls (n)	45% (359)	45% (81)	45% (278)	56% (26)	0.95
Mean MUAC in cm [95% CI]	11.2 [11.1 - 11.3]	10.5 [10.36 - 10.7]	11.4 [11.3 -11.5]	11.2 [10.9 – 11.5]	<0.001
Mean weight-for-age z-score [95% CI]	-4.01 [-4.11 – -3.92]	-4.51 [-4.72 – -4.31]	-3.92 [-4.03 – -3.80]	-3.56 [-3.94 – -3.92]	<0.001
% mortality (n)	15% (127)	26% (47)	10% (64)	34% (16)	<0.001 ^o
% oedematous (n)	31% (264)	30% (54)	33% (203)	15% (7)	0.50
Site					
Coast Provincial General Hospital, Kenya	39% (329)	25% (45)	40% (247)	80% (37)	<i>Reference</i>
Kilifi County Hospital, Kenya	22% (187)	22% (40)	23% (145)	4% (2)	0.08
Queen Elizabeth Central Hospital, Malawi	39% (327)	52% (94)	36% (226)	15% (7)	<0.001

590 *comparison between HIV(+) and HIV(-); ^oadjusted for age, sex and site of recruitment

591

592

593 Table 2. Patient characteristics of those subjected to proteomics analysis

	All	HIV (+)	HIV (-)	<i>p</i> *
n	167	54	113	
Median age in months [IQR]	15 [10 – 26]	15 [10 – 26]	15 [10 – 24]	0.433
n girls (%)	76 (45%)	27 (50%)	49 (43%)	0.506
Mean MUAC at admission (cm) [95% CI]	10.9 [10.7 - 11.1]	10.2 [9.8 - 10.5]	11.3 [11.0 - 11.5]	<0.001
% oedematous (n)	49 (29%)	15 (28%)	34 (30%)	0.856
% mortality (n)	79 (47%)	36 (67%)	43 (38%)	<0.001^o

594 *comparison between HIV(+) and HIV(-), ^oadjusted for age, sex, site of recruitment, oedema

595
596

597 Table 3. Nutritional management protocol for children with severe acute malnutrition [46]

	Stabilization phase	In-patient Rehabilitation phase	Out-patient Rehabilitation phase
	<i>Days 1 - 7</i>	<i>Weeks 2 - 6</i>	<i>Lengths vary depending on site</i>
Complicated SAM	F75	F100	RUTF
Uncomplicated SAM	-	-	RUTF
<i>Composition</i>			
Energy (kcal per 100 mL F75/F100 or 100 g RUTF)	75	100	5.2 – 5.5
Protein (% total energy)	5	12	10 – 12
Fat (% total energy)	32	53	45 - 60

598

599
600

Supplementary Table 1. Prior use of anti-retroviral treatment among all HIV (+) children included in the clinical trial

	Prior HIV treatment*			
	HAART	NVP only	ART naïve	Unknown
n (%) ^o	53 (29%)	7 (4%)	90 (50%)	29 (16%)
Mean MUAC at admission (cm) [95% CI]	10.9 [10.5 - 11.4]	9.8 [8.9 - 10.6]	10.5 [10.2 - 10.8]	9.6 [8.1 - 11.1]
Mortality n (%)	10 (18%)	1 (28%)	25 (28%)	1 (25%)
Odds ratio for mortality [95% CI]	0.97 [0.82 - 1.12] p=0.63 [#]	-	Reference	1.07 [0.88 - 1.30] p=0.45 [#]

601 *HAART - highly active antiretroviral therapy; NVP – Nevirapine; [#] adjusted for age, sex, site and oedema
602

603 Supplementary table 2. Association between individual proteins to HIV status
604

Uniprot accession	Protein code	Protein names	log FC*	p°
P05109	S100A8	Protein S100-A8 (Calgranulin-A) (Calprotectin L1L subunit) (Cystic fibrosis antigen) (CFAG) (Leukocyte L1 complex light chain) (Migration inhibitory factor-related protein 8) (MRP-8) (p8) (S100 calcium-binding protein A8) (Urinary stone protein band A)	0.56	0.00
P06702	S100A9	Protein S100-A9 (Calgranulin-B) (Calprotectin L1H subunit) (Leukocyte L1 complex heavy chain) (Migration inhibitory factor-related protein 14) (MRP-14) (p14) (S100 calcium-binding protein A9)	0.55	0.00
P01708		Immunoglobulin lambda variable 2-11 (Ig gamma lambda chain V-II region DOT) (Ig lambda chain V-II region BOH) (Ig lambda chain V-II region BUR) (Ig lambda chain V-II region NIG-58) (Ig lambda chain V-II region TRO) (Ig lambda chain V-II region WIN)	0.59	0.01
P04275	VWF	von Willebrand factor (vWF) [Cleaved into: von Willebrand antigen 2 (von Willebrand antigen II)]	0.33	0.01
P01880	IGHD	Immunoglobulin heavy constant delta (Ig delta chain C region) (Ig delta chain C region NIG-65) (Ig delta chain C region WAH)	0.60	0.01
P23083	IGHV1-2	Immunoglobulin heavy variable 1-2 (Ig heavy chain V-I region ND) (Ig heavy chain V-I region V35)	0.60	0.01
P01598		Immunoglobulin kappa variable 1-5 (Ig kappa chain V-I region CAR) (Ig kappa chain V-I region EU) (Ig kappa chain V-I region HK102) (Ig kappa chain V-I region Kue)	0.55	0.01
P80748	IGLV3-21	Immunoglobulin lambda variable 3-21 (Ig lambda chain V-III region LOI) (Ig lambda chain V-V region DEL) (Ig lambda chain V-VII region MOT)	0.58	0.01
P13796	LCP1	Plastin-2 (L-plastin) (LC64P) (Lymphocyte cytosolic protein 1) (LCP-1)	0.28	0.01
P01857	IGHG1	Immunoglobulin heavy constant gamma 1 (Ig gamma-1 chain C region) (Ig gamma-1 chain C region EU) (Ig gamma-1 chain C region KOL) (Ig gamma-1 chain C region NIE)	0.64	0.01
P05362	ICAM1	Intercellular adhesion molecule 1 (ICAM-1) (Major group rhinovirus receptor) (CD antigen CD54)	0.28	0.01
P06318		Immunoglobulin lambda variable 6-57 (Ig lambda chain V-VI region AR) (Ig lambda	0.49	0.01

		chain V-VI region EB4) (Ig lambda chain V-VI region NIG-48) (Ig lambda chain V-VI region SUT) (Ig lambda chain V-VI region WLT)		
P18428	LBP	Lipopolysaccharide-binding protein (LBP)	0.31	0.01
P01834	IGKC	Immunoglobulin kappa constant (Ig kappa chain C region) (Ig kappa chain C region AG) (Ig kappa chain C region CUM) (Ig kappa chain C region EU) (Ig kappa chain C region OU) (Ig kappa chain C region ROY) (Ig kappa chain C region TI)	0.69	0.02
P0CG05		Immunoglobulin lambda constant 3 (Ig lambda chain C region DOT) (Ig lambda chain C region NEWM) (Ig lambda-3 chain C regions)	0.67	0.02
P0CG05		Immunoglobulin lambda constant 2 (Ig lambda chain C region Kern) (Ig lambda chain C region NIG-64) (Ig lambda chain C region SH) (Ig lambda chain C region X) (Ig lambda-2 chain C region)	0.67	0.02
B9A064	IGLL5	Immunoglobulin lambda-like polypeptide 5 (G lambda-1) (Germline immunoglobulin lambda 1)	0.60	0.02
H9KV70		Deleted.	0.27	0.02
P01597	IGKV1-39	Immunoglobulin kappa variable 1-39 (Ig kappa chain V-I region DEE) (Ig kappa chain V-I region Hau) (Ig kappa chain V-I region Mev) (Ig kappa chain V-I region OU) (Ig kappa chain V-I region Walker)	0.47	0.02
P01714	IGLV3-19	Immunoglobulin lambda variable 3-19 (Ig lambda chain V-III region SH)	0.54	0.02
P06331	IGHV4-34	Immunoglobulin heavy variable 4-34 (Ig heavy chain V-II region ARH-77)	0.49	0.02
P19652	ORM2	Alpha-1-acid glycoprotein 2 (AGP 2) (Orosomucoid-2) (OMD 2)	0.20	0.02
P01610		Immunoglobulin kappa variable 1-17 (Ig kappa chain V-I region Gal) (Ig kappa chain V-I region WEA)	0.52	0.02
P01781		Immunoglobulin heavy variable 3-7 (Ig heavy chain V-III region GAL) (Ig heavy chain V-III region GAR) (Ig heavy chain V-III region JON)	0.55	0.02
P02741	CRP	C-reactive protein [Cleaved into: C-reactive protein(1-205)]	0.51	0.02
P01717	IGLV3-25	Immunoglobulin lambda variable 3-25 (Ig lambda chain V-IV region Hil)	0.46	0.02
P01719		Immunoglobulin lambda variable 3-21 (Ig lambda chain V-III region LOI) (Ig lambda chain V-V region DEL) (Ig lambda chain V-VII region MOT)	0.44	0.02

P06681	C2	Complement C2 (EC 3.4.21.43) (C3/C5 convertase) [Cleaved into: Complement C2b fragment; Complement C2a fragment]	0.15	0.02
Q15848	ADIPOQ	Adiponectin (30 kDa adipocyte complement-related protein) (Adipocyte complement-related 30 kDa protein) (ACRP30) (Adipocyte, C1q and collagen domain-containing protein) (Adipose most abundant gene transcript 1 protein) (apM-1) (Gelatin-binding protein)	-0.23	0.02
P04208		Immunoglobulin lambda variable 1-47 (Ig lambda chain V-I region HA) (Ig lambda chain V-I region WAH)	0.53	0.02
Q15485	FCN2	Ficolin-2 (37 kDa elastin-binding protein) (Collagen/fibrinogen domain-containing protein 2) (EBP-37) (Ficolin-B) (Ficolin-beta) (Hucolin) (L-ficolin) (Serum lectin p35)	0.26	0.03
P18135		Immunoglobulin kappa variable 3-20 (Ig kappa chain V-III region B6) (Ig kappa chain V-III region GOL) (Ig kappa chain V-III region HAH) (Ig kappa chain V-III region HIC) (Ig kappa chain V-III region IARC/BL41) (Ig kappa chain V-III region NG9) (Ig kappa chain V-III region SIE) (Ig kappa chain V-III region Ti) (Ig kappa chain V-III region WOL)	0.57	0.03
P01613		Immunoglobulin kappa variable 1D-33 (Ig kappa chain V-I region AG) (Ig kappa chain V-I region Bi) (Ig kappa chain V-I region Lay) (Ig kappa chain V-I region Ni) (Ig kappa chain V-I region Rei) (Ig kappa chain V-I region Roy) (Ig kappa chain V-I region Scw) (Ig kappa chain V-I region WAT)	0.45	0.04
P01602	IGKV1-5	Immunoglobulin kappa variable 1-5 (Ig kappa chain V-I region CAR) (Ig kappa chain V-I region EU) (Ig kappa chain V-I region HK102) (Ig kappa chain V-I region Kue)	0.55	0.04
P04211	IGLV7-43	Immunoglobulin lambda variable 7-43 (Ig lambda chain V region 4A)	0.49	0.04
P01042_2	KNG1	Kininogen-1 (Alpha-2-thiol proteinase inhibitor) (Fitzgerald factor) (High molecular weight kininogen) (HMWK) (Williams-Fitzgerald-Flaujeac factor) [Cleaved into: Kininogen-1 heavy chain; T-kinin (Ile-Ser-Bradykinin); Bradykinin (Kallidin I); Lysyl-bradykinin (Kallidin II); Kininogen-1 light chain; Low molecular weight growth-promoting factor]	-0.28	0.04
H0YGL9		Deleted.	0.82	0.04
A0M8Q6	IGLC7	Immunoglobulin lambda constant 7 (Ig	0.54	0.05

		lambda-7 chain C region)		
P01617		Immunoglobulin kappa variable 2D-28 (Ig kappa chain V-II region FR) (Ig kappa chain V-II region GM607) (Ig kappa chain V-II region MIL) (Ig kappa chain V-II region TEW)	0.37	0.05
P01620		Immunoglobulin kappa variable 3-20 (Ig kappa chain V-III region B6) (Ig kappa chain V-III region GOL) (Ig kappa chain V-III region HAH) (Ig kappa chain V-III region HIC) (Ig kappa chain V-III region IARC/BL41) (Ig kappa chain V-III region NG9) (Ig kappa chain V-III region SIE) (Ig kappa chain V-III region Ti) (Ig kappa chain V-III region WOL)	0.44	0.05
P01702		Immunoglobulin lambda variable 1-51 (Ig lambda chain V-I region BL2) (Ig lambda chain V-I region EPS) (Ig lambda chain V-I region NEW) (Ig lambda chain V-I region NIG-64)	0.65	0.05
Q6UXB8_2	PI-16	Peptidase inhibitor 16 (PI-16) (Cysteine-rich secretory protein 9) (CRISP-9) (PSP94-binding protein) (CD antigen CD364)	-0.22	0.05
P01876	IGHA1	Immunoglobulin heavy constant alpha 1 (Ig alpha-1 chain C region) (Ig alpha-1 chain C region BUR) (Ig alpha-1 chain C region TRO)	0.51	0.05
P04196	HRG	Histidine-rich glycoprotein (Histidine-proline-rich glycoprotein) (HPRG)	-0.26	0.05
P04433	IGKV3-11	Immunoglobulin kappa variable 3-11 (Ig kappa chain V-III region VG)	0.57	0.05
P06310	IGKV2-30	Immunoglobulin kappa variable 2-30 (Ig kappa chain V-II region RPMI 6410)	0.52	0.05
G8JLA8		Deleted.	0.11	0.07
P01034	CST3	Cystatin-C (Cystatin-3) (Gamma-trace) (Neuroendocrine basic polypeptide) (Post-gamma-globulin)	0.16	0.07
P01765		Immunoglobulin heavy variable 3-23 (Ig heavy chain V-III region LAY) (Ig heavy chain V-III region POM) (Ig heavy chain V-III region TEI) (Ig heavy chain V-III region TIL) (Ig heavy chain V-III region TUR) (Ig heavy chain V-III region VH26) (Ig heavy chain V-III region WAS) (Ig heavy chain V-III region ZAP)	0.49	0.07
P04003	C4BPA	C4b-binding protein alpha chain (C4bp) (Proline-rich protein) (PRP)	0.10	0.07
P01743	IGHV1-46	Immunoglobulin heavy variable 1-46 (Ig heavy chain V-I region DOT) (Ig heavy chain V-I region HG3) (Ig heavy chain V-I region Mot)	0.45	0.07

P01031	C5	Complement C5 (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4) [Cleaved into: Complement C5 beta chain; Complement C5 alpha chain; C5a anaphylatoxin; Complement C5 alpha' chain]	0.07	0.07
P01764	IGHV3-23	Immunoglobulin heavy variable 3-23 (Ig heavy chain V-III region LAY) (Ig heavy chain V-III region POM) (Ig heavy chain V-III region TEI) (Ig heavy chain V-III region TIL) (Ig heavy chain V-III region TUR) (Ig heavy chain V-III region VH26) (Ig heavy chain V-III region WAS) (Ig heavy chain V-III region ZAP)	0.49	0.07
P01766	IGHV3-13	Immunoglobulin heavy variable 3-13 (Ig heavy chain V-III region BRO)	0.41	0.07
P01767	IGHV3-53	Immunoglobulin heavy variable 3-53 (Ig heavy chain V-III region BUT)	0.31	0.07
P02748	C9	Complement component C9 [Cleaved into: Complement component C9a; Complement component C9b]	0.12	0.07
Q06033_2		Inter-alpha-trypsin inhibitor heavy chain H3 (ITI heavy chain H3) (ITI-HC3) (Inter-alpha-inhibitor heavy chain 3) (Serum-derived hyaluronan-associated protein) (SHAP)	0.13	0.07
F5H6I0	B2M	Beta-2-microglobulin	0.14	0.07
P01871	IGHM	Immunoglobulin heavy constant mu (Ig mu chain C region) (Ig mu chain C region BOT) (Ig mu chain C region GAL) (Ig mu chain C region OU)	0.44	0.07
P08571	CD14	Monocyte differentiation antigen CD14 (Myeloid cell-specific leucine-rich glycoprotein) (CD antigen CD14) [Cleaved into: Monocyte differentiation antigen CD14, urinary form; Monocyte differentiation antigen CD14, membrane-bound form]	0.13	0.08
O00391_2		Sulfhydryl oxidase 1 (hQSOX) (EC 1.8.3.2) (Quiescin Q6)	0.11	0.08
P04206		Immunoglobulin kappa variable 3-20 (Ig kappa chain V-III region B6) (Ig kappa chain V-III region GOL) (Ig kappa chain V-III region HAH) (Ig kappa chain V-III region HIC) (Ig kappa chain V-III region IARC/BL41) (Ig kappa chain V-III region NG9) (Ig kappa chain V-III region SIE) (Ig kappa chain V-III region Ti) (Ig kappa chain V-III region WOL)	0.34	0.08
P07225	PROS1	Vitamin K-dependent protein S	0.04	0.08
P29622	SERPI4	Kallistatin (Kallikrein inhibitor) (Peptidase inhibitor 4) (PI-4) (Serpine A4)	-0.16	0.08
H0Y755	FCGR3A	Low affinity immunoglobulin gamma Fc	0.18	0.08

		region receptor III-A (Fragment)		
P10643	C7	Complement component C7	0.06	0.08
P01859	IGHG2	Immunoglobulin heavy constant gamma 2 (Ig gamma-2 chain C region) (Ig gamma-2 chain C region DOT) (Ig gamma-2 chain C region TIL) (Ig gamma-2 chain C region ZIE)	0.36	0.09
P01625		Immunoglobulin kappa variable 4-1 (Ig kappa chain V-IV region B17) (Ig kappa chain V-IV region JI) (Ig kappa chain V-IV region Len) (Ig kappa chain V-IV region STH)	0.38	0.09
O75636	FCN3	Ficolin-3 (Collagen/fibrinogen domain-containing lectin 3 p35) (Collagen/fibrinogen domain-containing protein 3) (Hakata antigen)	0.14	0.09
P25311	AZGP1	Zinc-alpha-2-glycoprotein (Zn-alpha-2-GP) (Zn-alpha-2-glycoprotein)	-0.14	0.09
Q96PD5	PGLYRP2	N-acetylmuramoyl-L-alanine amidase (EC 3.5.1.28) (Peptidoglycan recognition protein 2) (Peptidoglycan recognition protein long) (PGRP-L)	-0.14	0.10
P01019	AGT	Angiotensinogen (Serp1n A8) [Cleaved into: Angiotensin-1 (Angiotensin 1-10) (Angiotensin I) (Ang I); Angiotensin-2 (Angiotensin 1-8) (Angiotensin II) (Ang II); Angiotensin-3 (Angiotensin 2-8) (Angiotensin III) (Ang III) (Des-Asp[1]-angiotensin II); Angiotensin-4 (Angiotensin 3-8) (Angiotensin IV) (Ang IV); Angiotensin 1-9; Angiotensin 1-7; Angiotensin 1-5; Angiotensin 1-4]	0.21	0.11
P04040	CAT	Catalase (EC 1.11.1.6)	0.18	0.11
P01860	IGHG3	Immunoglobulin heavy constant gamma 3 (HDC) (Heavy chain disease protein) (Ig gamma-3 chain C region)	0.35	0.11
P01611	IGKV1D-12	Immunoglobulin kappa variable 1D-12 (Ig kappa chain V-I region Wes)	0.30	0.11
P07195	LDHB	L-lactate dehydrogenase B chain (LDH-B) (EC 1.1.1.27) (LDH heart subunit) (LDH-H) (Renal carcinoma antigen NY-REN-46)	0.14	0.11
Q9NZP8	C1RL	Complement C1r subcomponent-like protein (C1r-LP) (C1r-like protein) (EC 3.4.21.-) (C1r-like serine protease analog protein) (CLSPa)	0.10	0.11
P19823	ITIH2	Inter-alpha-trypsin inhibitor heavy chain H2 (ITI heavy chain H2) (ITI-HC2) (Inter-alpha-inhibitor heavy chain 2) (Inter-alpha-trypsin inhibitor complex component II) (Serum-derived hyaluronan-associated protein) (SHAP)	-0.16	0.12
P01624	IGKV3-15	Immunoglobulin kappa variable 3-15 (Ig kappa chain V-III region CLL) (Ig kappa	0.34	0.13

		chain V-III region POM)		
P02750	LRG1	Leucine-rich alpha-2-glycoprotein (LRG)	0.13	0.13
P20851_2		C4b-binding protein beta chain	0.03	0.13
P07360	C8G	Complement component C8 gamma chain	0.05	0.13
F5GY80	C8B	Complement component C8 beta chain	0.04	0.13
K7ER74	APOC4-APOC2	APOC4-APOC2 readthrough (NMD candidate)	0.24	0.13
P04406_2		Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (EC 1.2.1.12) (Peptidyl-cysteine S-nitrosylase GAPDH) (EC 2.6.99.-)	0.20	0.14
B4E1Z4		cDNA FLJ55673, highly similar to Complement factor B	0.03	0.15
P01011	SERPI3	Alpha-1-antichymotrypsin (ACT) (Cell growth-inhibiting gene 24/25 protein) (Serpins A3) [Cleaved into: Alpha-1-antichymotrypsin His-Pro-less]	0.13	0.15
D6RA08		Deleted.	0.12	0.16
P00915	CA1	Carbonic anhydrase 1 (EC 4.2.1.1) (Carbonate dehydratase I) (Carbonic anhydrase B) (CAB) (Carbonic anhydrase I) (CA-I)	0.10	0.16
P02747	C1QC	Complement C1q subcomponent subunit C	0.12	0.16
H0Y612	TRIM33	E3 ubiquitin-protein ligase TRIM33 (Fragment)	0.15	0.17
P07359	GP1BA	Platelet glycoprotein Ib alpha chain (GP-Ib alpha) (GPIb-alpha) (GPIbA) (Glycoprotein Ibalph) (Antigen CD42b-alpha) (CD antigen CD42b) [Cleaved into: Glycocalicin]	0.06	0.17
P02749	APOH	Beta-2-glycoprotein 1 (APC inhibitor) (Activated protein C-binding protein) (Anticardiolipin cofactor) (Apolipoprotein H) (Apo-H) (Beta-2-glycoprotein I) (B2GPI) (Beta(2)GPI)	-0.20	0.18
P22792	CPN2	Carboxypeptidase N subunit 2 (Carboxypeptidase N 83 kDa chain) (Carboxypeptidase N large subunit) (Carboxypeptidase N polypeptide 2) (Carboxypeptidase N regulatory subunit)	0.04	0.19
Q6EMK4	VASN	Vasorin (Protein slit-like 2)	0.06	0.19
B7ZKJ8	ITIH4	ITIH4 protein (Inter-alpha-trypsin inhibitor heavy chain H4)	0.11	0.19
O14791_3		Apolipoprotein L1 (Apolipoprotein L) (Apo-L) (ApoL) (Apolipoprotein L-I) (ApoL-I)	0.08	0.19
P02649	APOE	Apolipoprotein E (Apo-E)	0.16	0.19
P55056	APOC4	Apolipoprotein C-IV (Apo-CIV) (ApoC-IV) (Apolipoprotein C4)	0.15	0.19
P05546	SERPIND1	Heparin cofactor 2 (Heparin cofactor II) (HC-II) (Protease inhibitor leuserpin-2) (HLS2) (Serpins D1)	-0.22	0.19
P06276	BCHE	Cholinesterase (EC 3.1.1.8) (Acylcholine	-0.19	0.21

		acylhydrolase) (Butyrylcholine esterase) (Choline esterase II) (Pseudocholinesterase)		
P48740	MASP1	Mannan-binding lectin serine protease 1 (EC 3.4.21.-) (Complement factor MASP-3) (Complement-activating component of Ra-reactive factor) (Mannose-binding lectin-associated serine protease 1) (MASP-1) (Mannose-binding protein-associated serine protease) (Ra-reactive factor serine protease p100) (RaRF) (Serine protease 5) [Cleaved into: Mannan-binding lectin serine protease 1 heavy chain; Mannan-binding lectin serine protease 1 light chain]	0.04	0.23
P20742	PZP	Pregnancy zone protein (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 6)	0.12	0.25
P02766	TTR	Transthyretin (ATTR) (Prealbumin) (TBPA)	-0.18	0.27
P32119	PRDX2	Peroxiredoxin-2 (EC 1.11.1.15) (Natural killer cell-enhancing factor B) (NKEF-B) (PRP) (Thiol-specific antioxidant protein) (TSA) (Thioredoxin peroxidase 1) (Thioredoxin-dependent peroxide reductase 1)	0.02	0.30
P01833	PIGR	Polymeric immunoglobulin receptor (PIgR) (Poly-Ig receptor) (Hepatocellular carcinoma-associated protein TB6) [Cleaved into: Secretory component]	0.25	0.30
P02745	C1QA	Complement C1q subcomponent subunit A	0.11	0.31
P19320_3		Vascular cell adhesion protein 1 (V-CAM 1) (VCAM-1) (INCAM-100) (CD antigen CD106)	0.13	0.31
P22352	GPX3	Glutathione peroxidase 3 (GPx-3) (GSHPx-3) (EC 1.11.1.9) (Extracellular glutathione peroxidase) (Plasma glutathione peroxidase) (GPx-P) (GSHPx-P)	-0.07	0.32
Q08380	LGALS3BP	Galectin-3-binding protein (Basement membrane autoantigen p105) (Lectin galactoside-binding soluble 3-binding protein) (Mac-2-binding protein) (MAC2BP) (Mac-2 BP) (Tumor-associated antigen 90K)	0.14	0.32
P12259	F5	Coagulation factor V (Activated protein C cofactor) (Proaccelerin, labile factor) [Cleaved into: Coagulation factor V heavy chain; Coagulation factor V light chain]	0.03	0.32
P07900	HSP90AA1	Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86) (HSP86) (Lipopolysaccharide-associated protein 2) (LAP-2) (LPS-associated protein 2) (Renal carcinoma antigen NY-REN-38)	0.14	0.34
P05452	CLEC3B	Tetranectin (TN) (C-type lectin domain family 3 member B) (Plasminogen kringle 4-	-0.14	0.35

		binding protein)		
P19827	ITIH1	Inter-alpha-trypsin inhibitor heavy chain H1 (ITI heavy chain H1) (ITI-HC1) (Inter-alpha-inhibitor heavy chain 1) (Inter-alpha-trypsin inhibitor complex component III) (Serum-derived hyaluronan-associated protein) (SHAP)	-0.13	0.36
O43866	CD5L	CD5 antigen-like (Apoptosis inhibitor expressed by macrophages) (hAIM) (CT-2) (IgM-associated peptide) (SP-alpha)	0.24	0.37
P00918	CA2	Carbonic anhydrase 2 (EC 4.2.1.1) (Carbonate dehydratase II) (Carbonic anhydrase C) (CAC) (Carbonic anhydrase II) (CA-II)	-0.03	0.37
P04075	ALDOA	Fructose-bisphosphate aldolase A (EC 4.1.2.13) (Lung cancer antigen NY-LU-1) (Muscle-type aldolase)	0.10	0.39
P07357	C8A	Complement component C8 alpha chain (Complement component 8 subunit alpha)	-0.01	0.39
H0YD13	CD44	CD44 antigen	-0.01	0.41
P02751_10		Fibronectin (FN) (Cold-insoluble globulin) (CIG) [Cleaved into: Anastellin; Ugl-Y1; Ugl-Y2; Ugl-Y3]		0.41
P01877	IGHA2	Immunoglobulin heavy constant alpha 2 (Ig alpha-2 chain C region) (Ig alpha-2 chain C region BUT) (Ig alpha-2 chain C region LAN)	0.32	0.41
P01042	KNG1	Kininogen-1 (Alpha-2-thiol proteinase inhibitor) (Fitzgerald factor) (High molecular weight kininogen) (HMWK) (Williams-Fitzgerald-Flaujeac factor) [Cleaved into: Kininogen-1 heavy chain; T-kinin (Ile-Ser-Bradykinin); Bradykinin (Kallidin I); Lysyl-bradykinin (Kallidin II); Kininogen-1 light chain; Low molecular weight growth-promoting factor]	-0.15	0.42
B0YIW2	APOC3	Apolipoprotein C-III (Apolipoprotein C-III variant 1)	0.17	0.43
E7EPZ9		Deleted.	0.05	0.43
P04114	APOB	Apolipoprotein B-100 (Apo B-100) [Cleaved into: Apolipoprotein B-48 (Apo B-48)]	0.06	0.43
P51884	LUM	Lumican (Keratan sulfate proteoglycan lumican) (KSPG lumican)	-0.14	0.43
Q5VY30	RBP4	Retinol-binding protein	-0.11	0.43
Q9Y5Y7	LYVE1	Lymphatic vessel endothelial hyaluronic acid receptor 1 (LYVE-1) (Cell surface retention sequence-binding protein 1) (CRSBP-1) (Extracellular link domain-containing protein 1) (Hyaluronic acid receptor)	0.14	0.44
P04264	KRT1	Keratin, type II cytoskeletal 1 (67 kDa cytokeratin) (Cytokeratin-1) (CK-1) (Hair	0.18	0.44

		alpha protein) (Keratin-1) (K1) (Type-II keratin Kb1)		
P04004	VTN	Vitronectin (VN) (S-protein) (Serum-spreading factor) (V75) [Cleaved into: Vitronectin V65 subunit; Vitronectin V10 subunit; Somatomedin-B]	0.01	0.46
C9JF17	APOD	Apolipoprotein D (Fragment)	-0.12	0.46
Q16610	ECM1	Extracellular matrix protein 1 (Secretory component p85)	0.03	0.46
B1AKG0	CFHR1	Complement factor H-related protein 1	0.08	0.47
P02679_2		Fibrinogen gamma chain	0.16	0.48
P01591	JCHAIN	Immunoglobulin J chain (Joining chain of multimeric IgA and IgM)	0.21	0.49
P35542	SAA4	Serum amyloid A-4 protein (Constitutively expressed serum amyloid A protein) (C-SAA)	-0.07	0.50
P02675	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	0.15	0.51
G3V2W1	SERPI10	Protein Z-dependent protease inhibitor (Serpine peptidase inhibitor, clade A (Alpha-1 antitrypsin, antitrypsin), member 10, isoform CRA_a)	0.03	0.51
P01008	SERPINC1	Antithrombin-III (ATIII) (Serpine C1)	-0.11	0.51
P60709	ACTB	Actin, cytoplasmic 1 (Beta-actin) [Cleaved into: Actin, cytoplasmic 1, N-terminally processed]	0.07	0.53
P15151_3		Poliovirus receptor (Nectin-like protein 5) (NECL-5) (CD antigen CD155)	0.02	0.54
P61626	LYZ	Lysozyme C (EC 3.2.1.17) (1,4-beta-N-acetylmuramidase C)	0.11	0.54
V9GYE7	CFHR2	Complement factor H-related protein 2	0.02	0.54
G3XAM2	CFI	Complement factor I (Complement factor I, isoform CRA_b)	-0.03	0.55
P69905	HBA1	Hemoglobin subunit alpha (Alpha-globin) (Hemoglobin alpha chain)	0.00	0.55
P69905	HBA2	Hemoglobin subunit alpha (Alpha-globin) (Hemoglobin alpha chain)	0.00	0.55
O95445	APOM	Apolipoprotein M (Apo-M) (ApoM) (Protein G3a)	-0.08	0.55
P02790	HPX	Hemopexin (Beta-1B-glycoprotein)	-0.10	0.56
P68871	HBB	Hemoglobin subunit beta (Beta-globin) (Hemoglobin beta chain) [Cleaved into: LVV-hemorphin-7; Spinorphin]	0.01	0.60
P00747	PLG	Plasminogen (EC 3.4.21.7) [Cleaved into: Plasmin heavy chain A; Activation peptide; Angiostatin; Plasmin heavy chain A, short form; Plasmin light chain B]	-0.09	0.61
P00748	F12	Coagulation factor XII (EC 3.4.21.38) (Hageman factor) (HAF) [Cleaved into:	0.02	0.61

		Coagulation factor XIIa heavy chain; Beta-factor XIIa part 1; Coagulation factor XIIa light chain (Beta-factor XIIa part 2)]		
Q92954_4		Proteoglycan 4 (Lubricin) (Megakaryocyte-stimulating factor) (Superficial zone proteoglycan) [Cleaved into: Proteoglycan 4 C-terminal part]	-0.10	0.61
P01023	A2M	Alpha-2-macroglobulin (Alpha-2-M) (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 5)	-0.06	0.63
P06396	GSN	Gelsolin (AGEL) (Actin-depolymerizing factor) (ADF) (Brevin)	-0.08	0.67
P0DJ18	SAA1	Serum amyloid A-1 protein (SAA) [Cleaved into: Amyloid protein A (Amyloid fibril protein AA); Serum amyloid protein A(2-104); Serum amyloid protein A(3-104); Serum amyloid protein A(2-103); Serum amyloid protein A(2-102); Serum amyloid protein A(4-101)]	0.11	0.68
P22891	PROZ	Vitamin K-dependent protein Z	-0.05	0.68
P27169	PON1	Serum paraoxonase/arylesterase 1 (PON 1) (EC 3.1.1.2) (EC 3.1.1.81) (EC 3.1.8.1) (Aromatic esterase 1) (A-esterase 1) (K-45) (Serum aryldialkylphosphatase 1)	-0.17	0.69
D6RF35	GC	Vitamin D-binding protein	-0.09	0.69
K7ERG9	CFD	Complement factor D	0.02	0.72
P00742	F10	Coagulation factor X (EC 3.4.21.6) (Stuart factor) (Stuart-Prower factor) [Cleaved into: Factor X light chain; Factor X heavy chain; Activated factor Xa heavy chain]	0.03	0.72
P01024	C3	Complement C3 (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1) [Cleaved into: Complement C3 beta chain; C3-beta-c (C3bc); Complement C3 alpha chain; C3a anaphylatoxin; Acylation stimulating protein (ASP) (C3adesArg); Complement C3b alpha' chain; Complement C3c alpha' chain fragment 1; Complement C3dg fragment; Complement C3g fragment; Complement C3d fragment; Complement C3f fragment; Complement C3c alpha' chain fragment 2]	-0.08	0.72
P01861	IGHG4	Immunoglobulin heavy constant gamma 4 (Ig gamma-4 chain C region)	0.06	0.72
P02042	HBD	Hemoglobin subunit delta (Delta-globin) (Hemoglobin delta chain)	-0.03	0.72
P02760	AMBP	Protein AMBP [Cleaved into: Alpha-1-microglobulin (Protein HC) (Alpha-1 microglycoprotein) (Complex-forming glycoprotein heterogeneous in charge); Inter-	-0.10	0.72

		alpha-trypsin inhibitor light chain (ITI-LC) (Bikunin) (EDC1) (HI-30) (Uronic-acid-rich protein); Trypstatin]		
P02765	AHSG	Alpha-2-HS-glycoprotein (Alpha-2-Z-globulin) (Ba-alpha-2-glycoprotein) (Fetuin-A) [Cleaved into: Alpha-2-HS-glycoprotein chain A; Alpha-2-HS-glycoprotein chain B]	-0.07	0.72
P08185	SERPI6	Corticosteroid-binding globulin (CBG) (Serpins A6) (Transcortin)	0.00	0.72
P0C0L5	C4B	Complement C4-B (Basic complement C4) (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 3) [Cleaved into: Complement C4 beta chain; Complement C4-B alpha chain; C4a anaphylatoxin; C4b-B; C4d-B; Complement C4 gamma chain]	-0.01	0.72
P0C0L5	C4B_2	Complement C4-B (Basic complement C4) (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 3) [Cleaved into: Complement C4 beta chain; Complement C4-B alpha chain; C4a anaphylatoxin; C4b-B; C4d-B; Complement C4 gamma chain]	-0.01	0.72
Q9UGM5	FETUB	Fetuin-B (16G2) (Fetuin-like protein IRL685) (Gugu)	-0.12	0.72
B4E2S7		cDNA FLJ58780, highly similar to Homo sapiens lysosomal-associated membrane protein 2 (LAMP2), transcript variant LAMP2B, mRNA	0.00	0.74
E9PFZ2	CP	Ceruloplasmin	0.11	0.74
F5GXS5		Deleted.	0.04	0.74
P14151	SELL	L-selectin (CD62 antigen-like family member L) (Leukocyte adhesion molecule 1) (LAM-1) (Leukocyte surface antigen Leu-8) (Leukocyte-endothelial cell adhesion molecule 1) (LECAM1) (Lymph node homing receptor) (TQ1) (gp90-MEL) (CD antigen CD62L)	0.01	0.74
P36955	SERPINF1	Pigment epithelium-derived factor (PEDF) (Cell proliferation-inducing gene 35 protein) (EPC-1) (Serpins F1)	0.00	0.74
Q04756	HGFAC	Hepatocyte growth factor activator (HGF activator) (HGFA) (EC 3.4.21.-) [Cleaved into: Hepatocyte growth factor activator short chain; Hepatocyte growth factor activator long chain]	-0.02	0.74
P05543	SERPI7	Thyroxine-binding globulin (Serpins A7) (T4-binding globulin)	-0.08	0.77
F8W1Q3		Biotinidase (Biotinase) (EC 3.5.1.12)	-0.01	0.78
O75882_3		Attractin (DPPT-L) (Mahogany homolog)	-0.02	0.78
P05155	SERPING	Plasma protease C1 inhibitor (C1 Inh)	0.02	0.78

	1	(C1Inh) (C1 esterase inhibitor) (C1-inhibiting factor) (Serpin G1)		
Q96IY4	CPB2	Carboxypeptidase B2 (EC 3.4.17.20) (Carboxypeptidase U) (CPU) (Plasma carboxypeptidase B) (pCPB) (Thrombin-activable fibrinolysis inhibitor) (TAFI)	-0.04	0.78
P07996	THBS1	Thrombospondin-1 (Glycoprotein G)	-0.08	0.79
P08603	CFH	Complement factor H (H factor 1)	0.01	0.79
P10909_4		Clusterin (Aging-associated gene 4 protein) (Apolipoprotein J) (Apo-J) (Complement cytolysis inhibitor) (CLI) (Complement-associated protein SP-40,40) (Ku70-binding protein 1) (NA1/NA2) (Sulfated glycoprotein 2) (SGP-2) (Testosterone-repressed prostate message 2) (TRPM-2) [Cleaved into: Clusterin beta chain (ApoJalpha) (Complement cytolysis inhibitor a chain); Clusterin alpha chain (ApoJbeta) (Complement cytolysis inhibitor b chain)]	-0.04	0.82
I3L145	SHBG	Sex hormone-binding globulin (Sex hormone-binding globulin, isoform CRA_a)	-0.08	0.83
K7ERI9	APOC1	Apolipoprotein C-I (Fragment)	0.09	0.83
P00736	C1R	Complement C1r subcomponent (EC 3.4.21.41) (Complement component 1 subcomponent r) [Cleaved into: Complement C1r subcomponent heavy chain; Complement C1r subcomponent light chain]	-0.05	0.83
P02775	PPBP	Platelet basic protein (PBP) (C-X-C motif chemokine 7) (Leukocyte-derived growth factor) (LDGF) (Macrophage-derived growth factor) (MDGF) (Small-inducible cytokine B7) [Cleaved into: Connective tissue-activating peptide III (CTAP-III) (LA-PF4) (Low-affinity platelet factor IV); TC-2; Connective tissue-activating peptide III(1-81) (CTAP-III(1-81)); Beta-thromboglobulin (Beta-TG); Neutrophil-activating peptide 2(74) (NAP-2(74)); Neutrophil-activating peptide 2(73) (NAP-2(73)); Neutrophil-activating peptide 2 (NAP-2); TC-1; Neutrophil-activating peptide 2(1-66) (NAP-2(1-66)); Neutrophil-activating peptide 2(1-63) (NAP-2(1-63))]	-0.08	0.83
Q13103	SPP2	Secreted phosphoprotein 24 (Spp-24) (Secreted phosphoprotein 2)	-0.02	0.83
P0COL4	C4A	Complement C4-A (Acidic complement C4) (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 2) [Cleaved into: Complement C4 beta chain; Complement C4-A alpha chain; C4a anaphylatoxin; C4b-A;	0.02	0.84

		C4d-A; Complement C4 gamma chain]		
E9PGP2		Deleted.	0.03	0.85
P15169	CPN1	Carboxypeptidase N catalytic chain (CPN) (EC 3.4.17.3) (Anaphylatoxin inactivator) (Arginine carboxypeptidase) (Carboxypeptidase N polypeptide 1) (Carboxypeptidase N small subunit) (Kininase-1) (Lysine carboxypeptidase) (Plasma carboxypeptidase B) (Serum carboxypeptidase N) (SCPN)	-0.01	0.85
P08697	SERPINF2	Alpha-2-antiplasmin (Alpha-2-AP) (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Serpine F2)	0.01	0.85
H0YAC1	KLKB1	Plasma kallikrein (Fragment)	-0.04	0.90
P00740_2		Coagulation factor IX (EC 3.4.21.22) (Christmas factor) (Plasma thromboplastin component) (PTC) [Cleaved into: Coagulation factor IXa light chain; Coagulation factor IXa heavy chain]	-0.01	0.90
P04180	LCAT	Phosphatidylcholine-sterol acyltransferase (EC 2.3.1.43) (Lecithin-cholesterol acyltransferase) (Phospholipid-cholesterol acyltransferase)	-0.01	0.90
P00739	HPR	Haptoglobin-related protein	0.03	0.93
P02743	APCS	Serum amyloid P-component (SAP) (9.5S alpha-1-glycoprotein) [Cleaved into: Serum amyloid P-component(1-203)]	0.03	0.94
P09871	C1S	Complement C1s subcomponent (EC 3.4.21.42) (C1 esterase) (Complement component 1 subcomponent s) [Cleaved into: Complement C1s subcomponent heavy chain; Complement C1s subcomponent light chain]	-0.08	1.00
P00450	CP	Ceruloplasmin (EC 1.16.3.1) (Ferroxidase)	-0.05	1.00
P00734	F2	Prothrombin (EC 3.4.21.5) (Coagulation factor II) [Cleaved into: Activation peptide fragment 1; Activation peptide fragment 2; Thrombin light chain; Thrombin heavy chain]	-0.05	1.00
P02774	GC	Vitamin D-binding protein (DBP) (VDB) (Gc protein-derived macrophage activating factor) (Gc-MAF) (GcMAF) (Gc-globulin) (Group-specific component) (Gc) (Vitamin D-binding protein-macrophage activating factor) (DBP-maf)	-0.06	1.00
P04217	A1BG	Alpha-1B-glycoprotein (Alpha-1-B glycoprotein)	-0.02	1.00
P06727	APOA4	Apolipoprotein A-IV (Apo-AIV) (ApoA-IV) (Apolipoprotein A4)	0.00	1.00
P13671	C6	Complement component C6	-0.05	1.00
P43652	AFM	Afamin (Alpha-albumin) (Alpha-Alb)	-0.07	1.00
P69891	HBG1	Hemoglobin subunit gamma-1 (Gamma-1-	-0.07	1.00

		globin) (Hb F Agamma) (Hemoglobin gamma-1 chain) (Hemoglobin gamma-A chain)		
--	--	---	--	--

605 *log fold change - positive value for log fold change indicate higher enrichment in HIV(+);
606 °false-discovery rate adjusted after logistic regression using inverse probability weighting
607 accounting for recruitment site, sex , age, HIV status, mid-upper arm circumference, and
608 presence of oedema